New Ultra-Sensitive Assays Aim to Improve Early Detection of Alzheimer’s and Parkinson’s Disease
Three new immunoassays targeting key neurodegeneration biomarkers require just 1 µL of plasma and run on standard laboratory instruments.
Latest Articles
Editor's Top Picks
Diabetes Testing Moves Earlier—and Gets More Complex
As the 2026 ADA Standards of Care emphasize earlier identification and more precise classification of diabetes, clinical laboratories are rethinking workflows, assay menus, and their role in detection.
Be the First to Know What’s Next in the Lab
Every week, we dig into the biggest shifts, breakthroughs, and tech transforming clinical diagnostics. Straightforward, insightful, and always relevant.Critical Resources
Diagnostic Innovations
HNL Lab Medicine Partners with Ibex to Bring AI Prostate Cancer Diagnostics to Its Labs
The Pennsylvania-based laboratory will integrate Ibex's AI solution for prostate biopsies and TURP specimens into its existing digital pathology infrastructure.
Equipment & Supply Spotlight
Sarstedt’s Tempus1800 Sample Transport System Earns Vizient Innovative Technology Contract
The Vizient Innovative Technology Program evaluates products submitted through client-led councils for their potential to improve clinical care, patient safety, and business operations.
News, Know-How & Standards
Disease Detection & Understanding
Researchers Develop First DNA Aptamers That Bind Alzheimer’s Blood Biomarker Neurofilament Light Chain
The newly identified aptamers match antibody-level binding strength and could support the development of lower-cost, point-of-care blood tests for neurodegeneration.
